A Phase 2 clinical trial showed that early treatment with the experimental oral therapy PrimeC slowed functional decline and reduced the risk of death or ALS complications for people with amyotrophic lateral sclerosis (ALS) compared with a six-month delay in treatment. Top-line results from the main Phase 2…
News
A brain implant to detect attempted finger movements can enable people paralyzed by conditions such as amyotrophic lateral sclerosis (ALS) to type on a computer, a study showed. The findings build on a rapidly growing field of research into so-called implantable brain-computer interfaces (iBCIs), in which electrodes are implanted…
Acurastem has received a research grant from Target ALS to develop potential therapies for amyotrophic lateral sclerosis (ALS) that target SYF2, a protein involved in regulating TDP-43 function. Abnormalities in the TDP-43 protein are a hallmark of ALS and are believed to play a central role in…
Amydis has received a $2.5 million grant from the National Institutes of Health (NIH) to develop a simple eye test that could help detect toxic deposits of the TDP-43 protein — a hallmark of amyotrophic lateral sclerosis (ALS) and several other neurodegenerative diseases. With the funding from the…
Keros Therapeutics is collaborating with Massachusetts General Hospital to design a clinical trial evaluating its therapy candidate rinvatercept in people with amyotrophic lateral sclerosis (ALS). According to the developer, the therapy may help preserve muscle strength and function, and improve quality of life, for those with the progressive…
Insmed has launched a first-in-human clinical trial evaluating its experimental gene therapy INS1202 in people with amyotrophic lateral sclerosis (ALS). The Phase 1 study, called ARMOR (NCT07290062), aims to enroll about 23 adults with ALS, ages 18 to 80, who have been living with the disease for…
At this year’s Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, researchers and clinicians are talking about the central role of patients, families, and caregivers in driving change for people living with neuromuscular diseases. Bionews, the parent company of this site, sat down with John F. Crowley, president and…
An experimental nerve-protecting therapy called RT1999 (smilagenin) will soon be tested in people with amyotrophic lateral sclerosis (ALS) as part of a U.K. platform trial designed to quickly screen potential ALS treatments. The study, called EXPERTS-ALS, is testing several experimental ALS therapies…
People with amyotrophic lateral sclerosis (ALS) who were exposed to smoke from wildfires prior to developing the disease are more than twice as likely to experience respiratory failure or death, according to a new analysis. The findings underscore the need for further research to understand how air pollution and…
The ALS Network will continue to host its ASK ME webinar series throughout 2026, featuring expert-led sessions on advocacy, care, research, and daily life with amyotrophic lateral sclerosis (ALS). This…
Recent Posts
- After 15 years as an ALS caregiver, I’m still learning from others
- Early PrimeC use slows ALS progression, reduces complication risk
- Learning ALS self-advocacy involves being a little pushy
- Brain implant decodes finger moves so paralyzed patients can type
- Grant funds new ALS treatment approach targeting TDP-43 pathway